Liver Transplantation News and Research

RSS

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer.

1 Sep 2015

Transplanting multi-layered sheet of liver cells into damaged liver improves function in test animals

Liver transplantation is currently the only established treatment for patients with end stage liver failure. However, this treatment is limited by the shortage of donors and the conditional integrity and suitability of the available organs. Transplanting donor hepatocytes (liver cells) into the liver as an alternative to liver transplantation also has drawbacks as the rate of survival of primary hepatocytes is limited and often severe complications can result from the transplantation procedure.

27 Aug 2015

Yale study identifies new barrier to caring for chronic hepatitis C patients

Nearly one in four patients with chronic hepatitis C (HCV) are denied initial approval for a drug therapy that treats the most common strain of the infection, according to a Yale School of Medicine study.

27 Aug 2015

Breath test for liver disease detection moves closer

Researchers at the University of Birmingham have published results that suggest a non-invasive breath test for liver disease using an IONICON PTR-MS.

From Ionicon Analytik Ges.m.b.H. 20 Aug 2015

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02.

3 Aug 2015

Researchers at Sydney’s Centenary Institute fight against hepatitis infection

Today is World Hepatitis Day. 400 million people around the world are currently living with hepatitis B or C. Each year, we see around 1.4 million people die from viral hepatitis. Researchers at Sydney’s Centenary Institute are working hard to change this.

28 Jul 2015

Mayo Clinic researchers test Spheroid Reservoir Bioartificial Liver to treat patients with acute liver failure

Approximately 30,000-40,000 people die from liver disease each year, according to the American Liver Foundation. For people who experience acute liver failure, the only proven treatment has been liver transplantation. Researchers at Mayo Clinic have developed and are testing an alternative to liver transplantation called the Spheroid Reservoir Bioartificial Liver that can support healing and regeneration of the injured liver, and improve outcomes and reduce mortality rates for patients with acute liver failure — without requiring a transplant.

20 Jul 2015

University of Pittsburgh surgeon receives Anthony Cerami Award in Translational Medicine

The Feinstein Institute for Medical Research and Molecular Medicine announced today that the fourth Anthony Cerami Award in Translational Medicine will be conferred to Thomas E. Starzl, MD, PhD, professor of surgery at the University of Pittsburgh School of Medicine. The award is in recognition of his research in organ transplantation and alloengraftment mechanisms.

26 Jun 2015

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

The All Wales Medicines Strategy Group has recommended Daklinza (daclatasvir) for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. The recommendation is specifically for patients with advanced liver disease, for whom treatment options can be limited.

5 Jun 2015

New research shows wide variation in organ donation rates across the country

More than 123,000 Americans are currently waiting for lifesaving organ transplants, but 21 patients die each day because there aren't enough organs to go around. New research shows wide variation in the number of eligible organ donors whose loved ones consent to organ donation across the country.

29 May 2015

UCLA researchers successfully measure liver function in potential organ donors using finger-probe device

A portable, finger-probe device successfully measured liver function in brain dead adult organ donors, a finding that could change the way organs are assessed and save thousands of dollars per transplant, a UCLA study has found.

29 May 2015

Study shows differences in rates of paracetamol-linked acute liver failure among European countries

A fifty-fold between-country difference in rates of paracetamol-induced acute liver failure that leads to liver transplant (ALFT) has been revealed by a study that compared patient data from seven countries at the request of the European Medicines Agency: France, Greece, Ireland, Italy, Netherlands, Portugal and the UK.

29 May 2015

CLDF collaborates with Walgreens to offer free rapid HCV testing

The Chronic Liver Disease Foundation announced today that it's collaborating with Walgreens to offer free hepatitis C (HCV) testing with the OraQuick HCV Rapid Test at more than 60 Walgreens retail pharmacies in 12 major cities throughout the country.

19 May 2015

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).

19 May 2015

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Exalenz Bioscience, a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study evaluating the potential of its BreathID test to diagnose nonalcoholic steatohepatitis (NASH).

6 May 2015

New study finds that sexual function in adult living donors lower at three months after transplant

A new study found that sexual function in adult living donors was lower at the evaluation phase and at three months following liver transplantation. Results published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, suggest that donor education prior to surgery may improve recovery and ease concerns about sexual function following the transplant.

29 Apr 2015

New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT).

25 Apr 2015

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.

23 Apr 2015

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Data revealed today at The International Liver Congress 2015 show that the long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with more than 95% of patients surviving at 5 years and a significant proportion of deaths coming from liver-unrelated causes.

23 Apr 2015

Transportable MP Airdrive device enhances donor liver viability for transplantation

A new device has demonstrated it has the potential to enhance the viability of donor livers for transplantation. Results revealed today at The International Liver Congress 2015 show that the transportable machine perfusion (MP) Airdrive is able to effectively maintain the quality of livers derived from donation after circulatory death (DCD).

23 Apr 2015

Liver Transplantation News and Research

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Transplanting multi-layered sheet of liver cells into damaged liver improves function in test animals

Yale study identifies new barrier to caring for chronic hepatitis C patients

Breath test for liver disease detection moves closer

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Researchers at Sydney’s Centenary Institute fight against hepatitis infection

Mayo Clinic researchers test Spheroid Reservoir Bioartificial Liver to treat patients with acute liver failure

University of Pittsburgh surgeon receives Anthony Cerami Award in Translational Medicine

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

New research shows wide variation in organ donation rates across the country

UCLA researchers successfully measure liver function in potential organ donors using finger-probe device

Study shows differences in rates of paracetamol-linked acute liver failure among European countries

CLDF collaborates with Walgreens to offer free rapid HCV testing

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

New study finds that sexual function in adult living donors lower at three months after transplant

New data supports use DAAs in patients with HCV recurrence following liver transplantation

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Transportable MP Airdrive device enhances donor liver viability for transplantation

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News